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Abstract
Motivation: Imaging demonstrates that preclinical and human tumors are heterogeneous, i.e. a sin-
gle tumor can exhibit multiple regions that behave differently during both development and also in
response to treatment. The large variations observed in control group, tumors can obscure detection
of significant therapeutic effects due to the ambiguity in attributing causes of change. This can hinder
development of effective therapies due to limitations in experimental design rather than due to thera-
peutic failure. An improved method to model biological variation and heterogeneity in imaging sig-
nals is described. Specifically, linear Poisson modeling (LPM) evaluates changes in apparent diffu-
sion co-efficient between baseline and 72 h after radiotherapy, in two xenograft models of colorectal
cancer. The statistical significance of measured changes is compared to those attainable using a con-
ventional t-test analysis on basic apparent diffusion co-efficient distribution parameters.
Results: When LPMs were applied to treated tumors, the LPMs detected highly significant changes.
The analyses were significant for all tumors, equating to a gain in power of 4-fold (i.e. equivalent to
having a sample size 16 times larger), compared with the conventional approach. In contrast,
highly significant changes are only detected at a cohort level using t-tests, restricting their potential
use within personalized medicine and increasing the number of animals required during testing.
Furthermore, LPM enabled the relative volumes of responding and non-responding tissue to be
estimated for each xenograft model. Leave-one-out analysis of the treated xenografts provided
quality control and identified potential outliers, raising confidence in LPM data at clinically relevant
sample sizes.
Availability and implementation: TINA Vision open source software is available from www.tina-vi
sion.net.
Contact: paul.tar@manchester.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Preclinical experiments and early clinical studies are essential for
understanding the fundamental mechanisms driving the growth of
malignant tumors and for assessing potential anti-cancer effects of
new therapies (Clohessy and Pandolfi, 2015; Conway et al., 2014;
Gibbs, 2000). In general, assessments are made by measuring tumor
growth curves, by evaluating cell or plasma based assays or tissue
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pathology at one or more time points and by non-invasive serial as-
sessment by imaging. In all of these approaches, significance testing
is performed typically on small numbers of subjects (Clohessy and
Pandolfi, 2015; Workman et al., 2006). This can result in low statis-
tical power. This is especially true in cases where data are complex
and variable. The limitations of small sample sizes motivate the
need for efficient use of data.
Differences between groups (i.e. control versus treatment, or one
thearapy versus another) are most commonly assessed using t-tests,
analysis of variance (ANOVA) or correlation analyses, which have
long been available within statistical packages (Kibby, 1986). These
statistical approaches are used as standard within clinical and pre-
clinical work because they facilitate estimation of confidence inter-
vals, Z-scores and P-values. These are essential outputs for the
assessment of treatment responses. However, these methods assume
Gaussian distributed data, which can be impossible to corroborate
using the small sample sizes often used within studies. More sophis-
ticated modern pattern recognition approaches are experimentally
applied to biomedical data for the purposes of prediction (e.g. Xia
et al., 2017), image segmentation (e.g. Zeng et al., 2017) and
data mining (e.g. Zong et al., 2017), for example. However, they
do not generally provide conventional confidence assessments
(e.g. P-values) and are therefore restricted to preliminary proof-
of-concept rather than clinical use.
Tumors are biologically heterogeneous, leading to numerous
modes of data variability that complicate analysis (Bedard et al.,
2013; Heppner, 1984). Research studies using genomics (Alizadeh
et al., 2015), tissue pathology (Gurcan et al., 2009) or clinical imag-
ing (O’Connor et al., 2015) identify and quantify spatial heterogen-
eity and have shown that heterogeneity metrics might provide
prognostic and predictive biomarkers of clinical outcome. Typically,
studies measure the degree of heterogeneity within individual
tumors or identify regions with certain cell populations that may
mediate response to therapy and resistance (Gerlinger et al., 2012).
However, tumor heterogeneity can also be a practical problem for
studying cancer biology. In small preclinical and clinical studies,
substantial spatial variation can occur in control and treatment
group tumors. This variation can obscure detection of significant
biological effects of therapy, such that therapies with potential clin-
ical benefit may be inadvertently halted in the developmental pipe-
line. To mitigate against this, information must be accumulated over
larger sample sizes to boost statistical power or unwanted sources of
variability must be modeled.
Imaging studies generally adopt one of two approaches: one ap-
proach attempts to identify the geographic sub-regions that drive re-
sponse to therapy, subsequent resistance and relapse during
treatment failure. This requires solutions to the significant chal-
lenges of both image segmentation (to identify voxels with common
structural or biological features) and voxel-to-voxel registration be-
tween time points. Pattern recognition techniques are often applied
to solve these problems. In the presence of heterogenous control
variability, it could be argued that an adversarial deep learning ap-
proach could be applied to classify treatment-affected voxels by
learning the invariant characteristics of treatment, while ignoring
the confounding changes of normal development. However, a seg-
mented image derived through such an approach is not necessarily
the best starting point for determining overall treated volumes and
P-values for the significance of changes. Additionally, training a
deep learning system typically requires far more data than is avail-
able in our problem domain.
In a second approach, imaging data can be regarded as a sample
from a distribution, providing histograms where the spatial structure
of a tumor is disregarded (Just, 2014). However, the complexities
(e.g. non-Gaussian nature) of imaging data make it difficult to use
simple histogram parameters to quantify therapy-induced changes in
tumor biology (O’connor, 2017). In this approach, basic distribu-
tion parameters, such as normalization (e.g. volume of tumor),
mean values or the location of percentiles are often used in conjunc-
tion with t-tests, ANOVA, and so on. This results in a large amount
of information being discarded regarding the exact shape and behav-
ior of individual histograms.
Given the properties of our target data (histograms of Poisson
samples), we sought to use linear Poisson modeling (hereafter, LPM)
(Deepaisarn et al., 2017; Tar and Thacker, 2014; Tar et al., 2015)
to quantify biological variation and to model uncertainties associ-
ated with data samples acquired in clinically relevant imaging meth-
ods. LPMs can be considered as an extension to Gaussian mixture
modeling, Dempster (1977), where the Gaussian sub-distributions
are replaced with arbitrary non-parametric probability functions.
The probability mass functions (PMFs) required to approximate the
data are determined using an independent component analysis
(Comon, 1994), designed for Poisson samples. LPM is a pattern rec-
ognition method specifically for quantitative work, facilitating the
estimation of confidence, Z-scores and P-values.
We hypothesized that LPM would provide a method for assess-
ing the volume of change within individual tumors, yielding a more
efficient and sensitive method of detecting response to therapy, com-
pared to conventional cohort-based analysis of imaging data. This
benefit was anticipated since LPM cannot only model volumetric
changes—allowing estimates of the proportion of tumor changing
after therapy—but can also model the effect of unwanted biological
variation due to tumor growth and heterogeneity found in control
data. We hypothesized that this benefit would transform the poten-
tial for image-based analyses to assess the preclinical development
of novel therapeutics.
2 Materials and methods
Imaging data were acquiredfor two murine xenograft models of
human colorectal cancer (LoVo and HCT116) treated with either a
single high-dose fraction of radiotherapy (RT) or sham (control).
About 8 and 13 controls were used for LoVo and HCT116, respect-
ively. A futher 10 LoVo and 15 HCT116 treated tumors were
imaged. These sample sizes are typical of those found within small
preclinical trials. The MRI biomarker apparent diffusion co-efficient
(ADC) (Padhani et al., 2009) was derived for images at baseline and
72 h after RT or sham. The tumor regions within each image were
manually segmented by a clinical expert (coauthor JPB O’Connor),
and the distribution of ADC values within each tumor was sampled
into 2 D histograms, with one axis being ADC and the other being
time (t¼0 h and t¼72 h), thus recording the ADC distributions
pre- and post-treatment. Figure 1 shows example spatial distribu-
tions of such tumor data before histogramming.
As a benchmark for comparison to our method, a conventional
analysis was performed. Tumors were paired between baseline and
t¼72 h, with changes in volume, in mean ADC value and in inter-
quartile ranges computed. The per-tumor changes measured within
the control groups were compared to those measured within the
treatment groups using t-tests. Additionally, LPM was used to con-
struct a linear model of variability in the control cohorts, which
were then extended to include additional variability found within
the treatment cohorts. The fully trained models were fitted to both
the control and treatment groups to estimate the relative volumes
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associated with normal untreated tumor development and volumes
associated with treatment effects. Per-tumor significances were com-
puted, as well as cohort level significances, for comparison to the
conventional t-test analyses.
Studies were performed in compliance with the NCRI Guidelines
for the welfare and use of animals in cancer research (Workman
et al., 2010) and with licenses issued under the UK Animals
(Scientific Procedures) Act 1986 (PPL 40/3212) following local
Ethical Committee review.
2.1 Tumor implantation and monitoring
LoVo and HCT116 colorectal carcinoma cells were cultured in
RPMI 1640 medium supplemented with 10% heat inactivated fetal
calf serum (FCS) at 37C in a humidified 5% CO2 incubator. Cells
were passaged every 2–3 days using TEG solution (0.25% trypsin,
0.1% EDTA and 0.05% Hanks’ balanced salt solution in PBS).
Tumor xenografts were initiated from 5  106 cells per mouse (in
0.1 mL serum-free culture medium) injected subcutaneous in female
nu/nu CBA mice aged 10 weeks old.
Tumor size was monitored using callipers and the formula for el-
lipsoid volume, V ¼ ðp=6ÞLWD, where L, W and D are the largest or-
thogonal dimensions of the ellipsoid. When tumors reached 300–400
mm3 in size, mice were randomized to sham or given tumor-localized
RT (single 10 Gy fraction) using a metal-ceramic MXR-320/36 X-ray
machine (320 kV, Comet AG, Switzerland). The RT was administered
under ambient conditions to restrained, non-anesthetized mice. The re-
strained mice were held in a lead-shielded support perpendicular to the
source. Irradiation was delivered at a dose rate of 0.75 Gy/min. Mice
were turned around halfway through the procedure to ensure a uni-
form tumor dose. Imaging was performed at baseline immediately
prior to RT and 72 h post RT along with calliper measurement of
tumor volume. After the second MRI scan, animals were killed hu-
manely by cervical dislocation without recovery from anesthesia.
2.2 MRI acquisition and analysis
Mice were anesthetized with isoflurane delivered through a nose
cone apparatus at 2 ml/min, in 100% oxygen gas as a carrier.
Respiration rate was monitored throughout the experiment by use
of an electronic respiratory monitor apparatus. A heated water bed
was provided to maintain the animals at constant temperature of
36C throughout each scan. MRI was performed on a 7 T Magnex
instrument (Magnex Scientific Ltd, Oxfordshire, UK) interfaced to a
Bruker Avance III console and gradient system (Bruker Corporation,
Ettlingen, Germany), using a volume transceiver coil. Whole scan
time was approximately 25 min per animal.
Diffusion-weighted imaging (TR/TE¼2250/20 ms; a ¼ 90;
b values 150, 500 and 1000 s/mm2 along one diffusion direction;
matrix 128  128 and FOV 2.56  2.56 cm; 15 contiguous slices of
0.6 mm thickness) was performed after localization with a T2-
weighted anatomical sequence (TR/TE¼2410/50; a ¼ 136:8; ma-
trix 256  256 and FOV 2.56  2.56 cm; 15 contiguous slices of
0.6 mm thickness). ADC maps were generated by selecting a region
of interest on the lowest b value image. Voxel-wise values of ADC
(Supplementary data file) were calculated using in-house software
across the tumor using a least squares fitting routine for the equation
S ¼ S0ebD, where S0 represents the signal intensity in the absence
of a diffusion sensitizing gradient, S is the signal intensity for a par-
ticular b value, b is the numerical value in s/mm2 and D is the appar-
ent diffusion coefficient (mm2/s).
To validate the ADC measurement in this protocol, measure-
ments were verified using an ice water phantom, consisting of an
inner chamber of ice water surrounded by a larger chamber of ice to
maintain the inner chamber water at approximately 0C (Doblas
et al., 2015).
Baseline and change in tumor volume and ADC (mean value and
IQR) parameters were compared between control and treated
tumors using Student’s t-test for independent samples in IBM SPSS
Statistics v.22 (Armonk, NY). All tests were two-tailed. These tests
were performed and combined to provide comparison with the stat-
istics derived from LPM (see below). In all tests, P<0.05 was con-
sidered to indicate statistical significance. Corrections for multiple
comparisons were applied where necessary.
2.3 LPM of ADC data
A linear Poisson model describes a set of histograms (i.e. ADC distri-
butions) using a linear combination of PMFs, where each PMF rep-
resents some sub-component (e.g. a mode of variability/behavior) of
the signal:
HðADC; tÞ 
XNC
C
PðADC; tjCÞQC þ
XNT
T
PðADC; tjTÞQT ; (1)
where HðADC; tÞ is the histogram bin recording the frequency of
observed ADC values within range ADC at time t; C is a label indi-
cating a component of control behavior; T is a label indicating a
component of treatment behavior, as determined by the additional
variability within the treatment group, i.e. the behavior in treated
cases that cannot be accounted for already by control behavior; PðA
DC; tjCÞ and PðADC; tjTÞ are the probabilities of observing an
ADC value in range at time t from control behavior or treatment
behavior; and QC and QT are the quantities of each component in
the data. There are NC control components and NT treatment com-
ponents. Each component can broadly be considered as a type of tis-
sue development in control or treatment, corresponding to a mode
of heterogeneous variability. The more complex a tumor and its
Fig. 1. Example spatial distributions of ADC values in selected tumors.
Visually, HCT116 tumors are more complex and variable than LoVo tumors
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response to treatment, the greater the number of components the
tumor needs in its model.
Given a set of control tumors, i 2 f1;2; . . . ; SCg (where SC is the
control cohort sample size) and treated tumors, j 2 f1;2; . . . ; STg
(where ST is the treatment cohort sample size), an LPM is used to
provide likelihood solutions to PMFs and quantities. Estimation of
quantities and probabilities are achieved using expectation
maximization to optimize the following extended maximum
likelihood for control cohorts:
lnL ¼
X
i;ADC;t
ln
XNC
C
PðADC; tjCÞQCi
" #
HiðADC; tÞ 
X
C
QCi (2)
and the following for treatment cohorts:
lnL ¼
X
j;ADC;t
ln
XNC
C
P ADC; tjCð ÞQCj þ
XNT
T
PðADC; tjTÞQTj
" #
(3)
HjðADC; tÞ 
X
C
QCj 
X
T
QTj:
Thus, the model is trained in two parts. Initially, NC terms are esti-
mated using only the control cohort as training data [Equation (2)].
Once the PMFs for control behavior have been learnt, these compo-
nents are automatically included as modes of behavior within the
treatment cohort. The additional NT components that describe the
extra variability expected due to treatment are then learnt using
the treatment cohort, keeping the original NC components as part of
the model [Equation (3)]. In this way, parts of a treated tumor’s ADC
distribution can be partitioned into quantities of responding and non-
responding behavior.
A model selection process identifies the optimum number of
LPM components required to describe the ADC distributions.
Multiple models are constructed with increasing numbers of compo-
nents, with the best fitting models being selected for use in subse-
quent analysis. The number of components required to describe
each class of response, i.e. NC for control and NC þNT for treat-
ment, is determined by adding additional components until the v2
per degree of freedom between LPM and ADC histograms reaches a
minimum, ideally at unity:
v2D ¼
1
D
X
ADC;t
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
HðADC; tÞp  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃMðADC; tÞp 2
r2ADC;t
; (4)
where D is the number of degrees of freedom and r2 is the variance
predicted on the residual. The square-roots are present to transform
the Poisson distributed histogram frequencies into Gaussian-like
variables to improve this figure of merit’s approximation to ideal v2
statistics, as described in Anscombe (1948).
Assuming independent Poisson errors (r2H  H), LPMs provide
estimates of uncertainties by summing the effects of individual
Poisson bins into quantity error covariances. This is achieved using
error propagation. The error covariance can be further scaled by v2D
(goodness-of-fit) computed from LPM-data residuals to boost errors
to better match actual distributions of true residuals, i.e. scaling fac-
tor that can be caused by the up-sampling of MRI data. A covari-
ance matrix for quantities, Q, can be estimated using
Cij ¼ v2D
X
m
@Qi
@HðADC; tÞ
 
@Qj
@HðADC; tÞ
 
r2H
 
; (5)
where C is the error covariance matrix for the estimated quantities.
The statistical significance of treatment response is computed by
dividing the sum of treatment quantities
P
T QT by the estimated
error on that total quantity. This provides a Z-score, indicating how
many standard deviations from zero the response is estimated to be.
2.4 Model validation
The null hypothesis from which P-values are computed is that
behavior is consistent with control, and that control behavior is pre-
dictable. This behavior must generalize to unseen control data. In
contrast, treatment behavior only needs to be different from control.
The validity of this null hypothesis relies upon there being no signifi-
cant changes in independent non-treatment groups. We used a com-
bination of control and leave-one-out testing to provide technical
validation.
Treatment models were fitted to control training data to ensure
the measured effects of treatment were consistent with zero (with
error bars). Additionally, if control LPM is representative of typical
non-treated tumors, then their application to independent data
should yield equivalent results to data from which the models were
original estimated. A leave-one-out analysis was therefore per-
formed in which multiple models were constructed, with each con-
trol tumor being excluded in turn, before being assessed as an
independent sample. This leave-one-out strategy in control data en-
ables stringent testing to be performed in numbers of datasets that
are typical of those used in preclinical cancer imaging experiments
(Bernsen et al., 2015). This approach also protects against false-
positive results through quality control (i.e. representativeness test-
ing) of training data.
3 Results
3.1 Cohort volumetrics and summary ADC detect
RT response
Volume and basic ADC distribution parameters demonstrated that
significant growth inhibition was induced by RT in both xenograft
models at 72 h, relative to control. In both LoVo and HCT116, RT
reduced volume, increased mean ADC value and increased IQR of
the ADC distribution, relative to control. Treatment effects were de-
tected at the cohort level, as summarized in Table 1, reaching high
levels of significance (P<0.000001). The Z-scores and P-values
were computed from t-tests on the three parameters individually
(changes in volume, mean and IQR). The combined Z-score and
P-value values show the significances attainable when the three param-
eters are considered jointly, assuming each provides independence evi-
dence of change. As t-tests are applied to the group, individual tumor
change assessments are not possible using this method.
Table 1. Conventional t-test analysis
Measurement Z score P-value
LoVo vol. change 3.3 0.001
LoVo mean ADC change 3.5 0.0004
LoVo IQR change 2.0 0.041
LoVo combined 5.2 <0.000001
HCT116 vol. change 4.6 0.0008
HCT116 mean ADC change 4.3 0.0009
HCT116 IQR change 2.1 0.047
HCT116 combined 8.1 <0.000001
Note: The cohort level significances are 5.2 SD change and 8.1 SD change
for LoVo and HCT116, respectively. These figures should be compared to the
cohort level significances of Tables 2 and 3.
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3.2 LPM identifies the varying complexity of different
xenograft models
For each xenograft model, an LPM was constructed independently
and the number of model components was selected on the basis of
leave-one-out cross validation. This yielded three components to de-
scribe ADC distributions in the LoVo control tumors, with an add-
itional two required for the variability caused by treatment. An
equivalent and independent process was performed for the HCT116
tumors. This yielded four components in control tumors and an add-
itional five for treatment response.
The plots in Figures 2 and 3 show these results in detail in terms
of goodness-of-fits (v2D) for models with different numbers of com-
ponents. We seek the number of components that gives the min-
imum. The best solutions are indicated with arrows: LoVo NC¼3
and NT¼2 (NC þNT ¼ 5 in the plot); HCT116 NC¼4 and NT¼5
(NC þNT ¼ 9 in the plot).
The HCT116 tumors are expected to be more complex than
LoVo, as they show a greater inter-quartile range of ADC values
and can be seen to be more heterogeneous upon visual inspection.
A more complex tumor is expected to require a greater number of
LPM components to be modeled. The LPM data indicate that the
HCT116 xenografts were more spatially complex than the LoVo
xenografts and that LPM can detect this differing level of tumor
complexity, which is expected of these particular tumors. The
greater number of components required to describe HCT116 tumors
reflects the higher variability that can be seen visually in Figure 1.
The ADC distributions associated with the extracted compo-
nents can be seen in Figures 4 and 5. Each component is a probabil-
ity distribution, showing the statistical correlations between ADC
values between the two time points. These correspond to the PðAD
C; tjTÞ and PðADC; tjCÞ parts of the model. The weighted sum of
these distributions describes the variability observed within the data.
Biologically, each component can be interpreted as a sub-population
of ADC values found within the tumors. The higher ADC values at
t¼72 are more probable, indicating greater diffusion due to less re-
stricted fluid movement.
3.3 LPM validation identifies outliers in control groups
We used control testing and a leave-one-out approach to validate
the ability of the model to distinguish data with different ADC dis-
tributions to ensure control growth was corrected accounted for.
Fig. 2. Model selection curves indicating necessary number of components to
describe control and treatment groups. Left: v2D as a function of NC for LoVo.
Right: v2D as a function of NC þNT for LoVo
Fig. 3. Model selection curves indicating necessary number of components to
describe control and treatment groups. Left: v2D as a function of NC for
HCT116. Right: v2D as a function of NC þNT for HCT116
Fig. 4. Estimated components (PMFS: P ðADC ; t jCÞ and P ðADC ; t jT Þ), one
color per component. Left and right plots indicate baseline and 72 h. Top:
LoVo control components. Bottom: LoVo treatment components
Fig. 5. Estimated components (PMFS: P ðADC ; t jCÞ and P ðADC ; t jT Þ), one
color per component. Left and right plots indicate baseline and 72 h. Top:
HCT116 control components. Bottom: HCT116 treatment components
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To do this, we applied fully trained models (i.e. leave-all-in) to both
LoVo and HCT116 control data, followed by reduced models where
each tumor in turn is excluded before being used as an independent
test data point (i.e. leave-one-out). Responses were computed in
each case with leave-all-in results plotted in the right of Figures 6
and 7. Leave-all-in and leave-one-out results are directly compared
in Tables 4 and 5.
A Z score is given by dividing the size of a response by 1 SD error
on that response. In cohorts of around 10, all control tumors would
be expected to have Z scores of <2. This was found for all but two
tumors (LoVo 4 and HCT116 12), with average Z scores from full
models of 1.05 for LoVo and 0.94 for HCT116. Differences
between alternative models (leave-all-in and each of the various
leave-one-out possibilities) were statistically equivalent, implying
that estimated volumes were the same, within limits of estimated
errors. These data show that the model performs as expected, cor-
rectly accounting for each control tumor distribution as being con-
structed of components from untreated voxel values.
The leave-one-out approach not only validates the LPM method
but also identifies outlier data in the control cohort. During full ana-
lysis LoVo control tumor 4 showed a Z score of 2.9 for estimated
treatment volume and HCT116 control tumor 12 showed a Z score
of 2.0. These increased to 5.2 and 3.5, respectively, for leave-one-
out analysis, implying differences from other control data. This
could be explained by the data being an atypical, yet otherwise
valid, control sample, which could have been better modeled using
additional training data. For the current study, we elected to leave
these data in the control group, to impose a ‘worst case scenario’ on
our data, since we are describing a new methodology. More reason-
ably, this can be explained by these two control tumors being
outliers.
Therefore, LPM with leave-one-out validation enables statistic-
ally robust identification of outliers in control data, which can be a
critical step in avoiding equivocal results in small low-powered pre-
clinical studies.
3.4 LPM quantifies the percentage responding volume
in each tumor
Non-responding tumor was defined by the sum of the control model
component volumes (
P
CQC) and responding tumor was defined by
the sum of the treated model component volumes (
P
T QT ). The
proportion of tumor changing with therapy was calculated, along
with error bars (right of Figs 6 and 7). All LoVo and HCT116
tumors treated with RT showed statistically significant volumes of
responding tumor, i.e. the responding volume was above zero, be-
yond the level expected by noise alone. For LoVo, proportion of vol-
ume responding to RT varied between 27.6 and 68.6% (median
responding volume 40.4%). For HCT116, proportion of volume re-
sponding to RT varied between 22.7 and 84.4% (median responding
volume 61.4%). In comparison, all control tumors (except outlier
LoVo control tumor 4) had responding volumes consistent with
zero. These measurements are possible with the LPM method, but
not the t-test method.
3.5 LPM biomarkers of response are more powerful
than conventional analyses
In LPM, the error estimates on measured affected volumes incorpor-
ate systematic processes associated with learning the model param-
eters (i.e. determination of PMFs), as well as the statistical errors on
weighting factors used to describe each case. LPM can capture the
uncertainties on the distribution components and the weighting fac-
tors using the error estimates provided by the method. This enables
construction of hypothesis tests for individual datasets, by testing
the null hypothesis (i.e. zero response) on a case by case basis. The
probability of the treatment volume being consistent with zero on
the basis of estimated error was measured. Tables 2 and 3 show the
individual and cohort significances and Tables 4 and 5 show the
control cohort responses for comparison.
The LPM approach implicitly combines information from vol-
ume and ADC change. To ensure a fair comparison between LPM
and conventional measures, we combined the significance for con-
ventional volume and ADC (mean and IQR), giving a total Z score
of 5.2 SD for LoVo (Table 1). LPM results showed higher Z score
and more significant P-values for many of the individual treated
tumors compared to the conventional cohort-level statistics for
imaging biomarkers.
The combined Z score from the LPM was 21.8 SD for LoVo
tumors. Since a linear increase in Z score requires a quadratic in-
crease in data quantity, approximately 17–18 times more data
(square of 21.8/5.2) would be needed for LoVo tumors to demon-
strate the same treatment effect with equivalent power using volume
and mean ADC compared to LPM. This equates to an increase in
power of approximately 4-fold. An equivalent comparison of sum-
mary statistics and LPM statistics in HCT116 xenografts treated
with RT showed a similar gain in statistical power. These data re-
veal that mathematical modeling of imaging data through LPM en-
ables substantial increase in statistical power to detect response to
therapy.
4 Discussion
In this study, we describe how modeling the spatial heterogeneity
present in imaging data can increase statistical power of identifying
response to therapy. We investigated a technique called LPM in a
Fig. 6. Volume response to treatment (i.e.
P
T QT ) for LoVo tumors. Left:
Treatment cohort, with significant non-zero values. Right: Control cohort,
with values consistent with zero (i.e. within level of predicted error) with pos-
sible outlier at tumor 4. All error bars show61 SD
Fig. 7. Volume response to treatment (i.e.
P
T QT ) for HCT116 tumors. Left:
Treatment cohort, with significant non-zero values. Right: control cohort, with
values consistent with zero (i.e. within level of predicted error). All error bars
show61 SD
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well understood biological paradigm, namely ADC as a response
biomarker following high-dose RT.
Next, we demonstrated that LPM could appropriately describe
ADC distributions of varying complexity, across two untreated
xenograft models, with multiple model components being deter-
mined to account for modes of tumor heterogeneity. We then
showed three important advantages of applying LPM to analyze the
ADC data, all of which would not be possible using conventional
image analysis methods.
First, in providing method technical validation, through a leave-
one-out approach, we showed that it was possible to detect outliers
in control groups. It is common to have variation in control group
imaging biomarker values and this can substantially limit the ability
of any biomarker to detect biological differences between small co-
horts of control and treated animals (de Jong et al., 2014). In the era
of personalized medicine that employs tumor models of increasing
biological relevance and complexity (Sharpless and Depinho, 2006),
the ability to exclude atypical tumors from cohort-wise analysis is of
increasing importance. LPM enables outliers to be identified and
excluded based on robust statistical methods.
Second, any pair (pre- and post-) of ADC values can be assigned
a probability (p-value or Z-score) that they are associated with vari-
ation observed within the control group, or are statistically different
and thus can be considered belonging to a treatment group. By cal-
culating the volume of voxels in each category, LPM quantifies the
minimal amount of responding tissue (i.e. a lower bound) that can
be detected; more voxels may respond but cannot be distinguished
from non-responding voxels within the distribution overlapping
with control. Here all tumors showed some response, but the range
of the lower bound on responding volumes varied by approximately
2.5-fold in LoVo and approximately 4-fold in HCT116.
Third, this feature enables response detection on a sample by
sample basis, without the need for spatial mapping, e.g. image seg-
mentation and pre- post- treatment coregistration. This is possible
since LPM models variation within control data and then can ac-
count for this in the treatment group, identifying the number of vox-
els that are different within the frequency distribution of data, as
opposed to the spatial distribution. The key finding of this study
was that LPM is substantially more powerful than conventional
cohort-based statistical methods for analysing imaging data. Indeed,
approximately 16–18 times as much data from conventional ana-
lyses (size and mean ADC) would be required to detect changes with
equivalent power compared to an LPM analysis, equating to a 4-fold
increase in power.
The implications of these data are substantial. Once a control
model is established, the need for similar animal numbers in the
Table 4. LoVo control cohort result significances
Tumor Z (Z) P (P) Effect
(%)
(%) Error
(%)
(%)
1 0.5 (1.2) 0.58 (0.20) 3.51 (23.92) 6.48 (18.86)
2 1.1 (1.0) 0.26 (0.31) 7.47 (8.89) 6.69 (8.75)
3 0.6 (0.5) 0.49 (0.57) 4.17 (5.95) 6.18 (10.73)
4 2.9 (5.2) 0.00 (0.00) 23.05 (32.73) 7.84 (6.29)
5 0.2 (0.0) 0.84 (0.97) 0.98 (0.38) 5.07 (11.83)
6 0.8 (0.3) 0.40 (0.72) 4.95 (9.24) 5.89 (26.15)
7 1.2 (0.4) 0.24 (0.68) 9.28 (6.10) 7.96 (15.17)
8 0.9 (0.5) 0.37 (0.56) 4.78 (7.99) 5.34% (13.76)
Note: Main figures show results for leave-all-in analysis. Figures in brack-
ets show leave-one-out results, where the model was trained on all except the
current tumor before being applied to the current tumor.
Table 5. HCT116 control cohort result significances
Tumor Z (Z) P (P) Effect
(%)
(%) Error
(%)
(%)
1 0.5 (0.1) 0.59 (0.86) 8.18 (10.29) 15.53 (59.55)
2 0.6 (0.3) 0.55 (0.70) 6.43 (7.41) 11.00 (19.52)
3 0.8 (1.0) 0.42 (0.29) 11.57 (23.31) 14.48 (22.07)
4 0.9 (0.7) 0.39 (0.44) 9.14 (7.97) 10.70 (10.53)
5 0.2 (0.3) 0.80 (0.71) 6.84 (13.61) 27.93 (36.93)
6 1.4 (1.8) 0.15 (0.58) 12.55 (29.65) 8.74 (15.65)
7 0.8 (0.5) 0.41 (0.56) 15.10 (16.67) 18.36 (29.09)
8 1.4 (2.2) 0.14 (0.02) 18.18 (36.09) 12.62 (16.05)
9 1.7 (1.4) 0.08 (0.16) 17.09 (20.52) 9.89 (14.62)
10 0.6 (0.8) 0.54 (0.37) 9.45 (13.43) 15.84 (15.19)
11 1.0 (0.8) 0.30 (0.39) 7.04 (20.15) 6.89 (23.91)
12 2.0 (3.5) 0.04 (0.00) 24.50 (36.00) 12.01 (10.10)
13 0.3 (0.0) 0.78 (0.96) 3.34 (2.91) 12.14 (69.60)
Note: Main figures show results for leave-all-in analysis. Figures in brack-
ets show leave-one-out results, where the model was trained on all except the
current tumor before being applied to the current tumor.
Table 2. LoVo treatment cohort result significances
Tumor Z score P-value Effect (%) Error (%)
1 8.5 <0.000001 45.98 5.40
2 8.8 <0.000001 44.59 5.09
3 3.4 0.000667 35.64 10.47
4 5.9 <0.000001 31.37 5.24
5 5.3 <0.000001 40.41 7.57
6 6.1 <0.000001 35.77 5.87
7 6.1 <0.000001 65.75 10.80
8 8.6 <0.000001 68.64 7.94
9 8.5 <0.000001 55.51 6.50
10 5.4 <0.000001 27.57 5.10
Combined 21.8 <0.000001
Note: The cohort-level significance (bottom row) is approximately four
times that for LoVo in Table 1.
Table 3. HCT116 treatment cohort result significances
Tumor Z score P-value Effect (%) Error (%)
1 3.5 0.000453 66.66 19.01
2 3.1 0.002239 34.53 11.30
3 10.3 <0.000001 67.00 6.53
4 7.5 <0.000001 67.10 8.97
5 7.2 <0.000001 84.41 11.80
6 7.3 <0.000001 60.77 8.35
7 3.9 0.000072 49.04 12.36
8 8.3 <0.000001 49.71 6.01
9 7.3 <0.000001 70.58 9.67
10 20.1 <0.000001 83.89 4.18
11 4.9 <0.000001 40.94 8.32
12 9.9 <0.000001 75.82 7.61
13 3.7 0.000243 65.56 17.87
14 9.7 <0.000001 61.36 6.35
15 2.5 0.0111474 22.67 8.93
Combined 32.6 <0.000001
Note: The cohort-level significance (bottom row) is approximately four
times that for HCT116 in Table 1.
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treatment group is diminished considerably. Subsequent studies for
a known animal model would require a small number of new con-
trol animals (to establish equivalence with banked control data).
Then very small cohorts can be tested for a given therapy. In particu-
lar, LPM can identify response on a per tumor basis with greater sig-
nificance than seen in a conventional t-test analysis of control versus
treatment cohorts. This would allow reduction in animal numbers,
with welfare benefits (Workman et al., 2010), and the ability to
identify individual responders in small studies of therapies where
different tumors with varying biology are treated. This may be at-
tractive for avatar studies where patient derived samples are used to
generate PDx and CDx models (Malaney et al., 2014) and in co-
clinical trials where multiple therapies are tested against animal
models with different genetic knockdown/knockout features
(Clohessy and Pandolfi, 2015).
The automatic process of building an individual LPM model and
computing its errors takes <5 min on typical hardware. However,
the process must be performed multiple times during model selection
and validation. The model selection process for LoVo required 10
models to be constructed, whereas HCT116 required 11. Leave-one-
out validation required an additional eight models for LoVo and 13
for HCT116, representing each possible leave-one-out control com-
bination. Total run-time was <4 h, making it feasible to perform
multiple complete analyses per day.
The LPM method described here has some limitations. As the
volume of responding tissue is computed by excluding all variation
that cannot be interpreted as normal control development, this value
is strictly a lower bound. This bound however, is appropriate for use
as part of the null hypothesis test. Our method determines this esti-
mate without labeling individual voxels of data, but instead operates
by fitting the entire data ADC distributions, learning the correl-
ations between those from two time points. In so doing LPM can es-
timate the volume of treatment response without having to solve the
ill-posed problem of voxel to voxel registration—where investiga-
tors attempt to produce one-to-one mapping between voxels from
images at different time points in tumors that change in shape and
volume over time (O’connor, 2017). This does however prevent
LPM in its current form generating voxel level treatment response
maps, which might otherwise be assumed possible for a method
which estimates volume of treatment response.
If the control cohort is not sufficient to describe control variation
then treatment volume can be overestimated by inappropriately
attributing previously unseen control variation to treatment. This is
the same problem as missing high sources of control variation when
applying a conventional t-test, but with the problem multiplied for a
higher dimensional model. Translation of the technique requires fur-
ther technical and biological validation, though showing consistency
in results across multiple models and therapies, with data from dif-
ferent laboratories (Doblas et al., 2015). Clinical application may
also be possible, with collection of the necessary data in an appro-
priate control group.
The method is protected from model construction problems that
avoid over-interpretation of results. For instance, a highly atypical
example will have a correspondingly high v2D, and since quantity
error covariances are scaled by this value, the statistical significance
of treatment estimates is penalized for poorly modeled data. Large
quantity errors can generally be attributed to poor models, for ex-
ample, with few control datasets, but this problem can be reduced
by adding additional (valid) training data. Equally, if contamination
in the form of outliers is included in control data, the additional
variability introduced in the control model reduces the ability to
measure treatment, again penalizing the statistical significance of
results. While this reduces the statistical power of the method, it in-
creases robustness by providing a working analysis which gives a
valid, yet more limited, lower bound on volume changes.
5 Conclusion
We have shown that LPM can remove unwanted biological vari-
ation in image data (from growth) for tumors of varying spatial
heterogeneity. This substantially increases sensitivity to treatment-
induced change, thus increasing statistical power. Once control
models are constructed, LPM enables significant changes to be de-
tected for single tumors. This has important implications for 3Rs
(specifically reduction in animals) and LPM may facilitate design of
complex preclinical avatar and co-clinical trial experiments by pro-
viding adequate power to small cohort sizes.
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